# Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma

> **NCT01213732** · PHASE1 · COMPLETED · sponsor: **Philogen S.p.A.** · enrollment: 19 (actual)

## Conditions studied

- Patients With Intransit Stage III/IV Melanoma

## Interventions

- **OTHER:** Isolated inferior limb perfusion

## Key facts

- **NCT ID:** NCT01213732
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-03
- **Final completion:** 2011-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-04-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01213732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01213732, "Phase 1 Dose-finding Study of L19TNFα Plus Melphalan Using Isolated Inferior Limb Perfusion (ILP) in Subjects With Intransit Stage III/IV Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01213732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*